Zigakibart

Summary

Zigakibart (CHEMBL5095316) is a phase-3 clinical-stage antibody; indicated across 2 conditions including iga glomerulonephritis and plasma cell myeloma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Indications: 2 conditions
• Clinical trials: 5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL5095316
Name	Zigakibart
Type	Antibody
Max phase	3

Also known as: Bion 1301, BION-1301, BION1301, C-90401, C90401, Zigakibart, ZIGAKIBART

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
IgA glomerulonephritis	3	MONDO:0005342	EFO:0004194
plasma cell myeloma	1	MONDO:0009693	EFO:0001378

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE3	2
PHASE1/PHASE2	1
PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05852938	PHASE3	ACTIVE_NOT_RECRUITING	A Study of Zigakibart in Adults With IgA Nephropathy
NCT06858319	PHASE3	RECRUITING	Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
NCT07146906	PHASE2	RECRUITING	A Study to Assess the Effects of Zigakibart on IgA Nephropathy.
NCT03340883	PHASE1/PHASE2	TERMINATED	Safety and Tolerability of BION-1301 in Adults With Relapsed or Refractory Multiple Myeloma (MM)
NCT05508204	PHASE1	COMPLETED	Open-label Safety and PK Study of BION-1301 in Japanese Healthy Subjects

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).